GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (TSE:4974) » Definitions » Cyclically Adjusted Revenue per Share

Takara Bio (TSE:4974) Cyclically Adjusted Revenue per Share : 円373.79 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Takara Bio Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Takara Bio's adjusted revenue per share for the three months ended in Mar. 2024 was 円114.362. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円373.79 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Takara Bio's average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 13.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Takara Bio was 14.40% per year. The lowest was 6.50% per year. And the median was 11.80% per year.

As of today (2024-06-04), Takara Bio's current stock price is 円1034.00. Takara Bio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was 円373.79. Takara Bio's Cyclically Adjusted PS Ratio of today is 2.77.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Takara Bio was 14.83. The lowest was 2.56. And the median was 9.45.


Takara Bio Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Takara Bio's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takara Bio Cyclically Adjusted Revenue per Share Chart

Takara Bio Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 234.32 254.20 295.42 350.47 373.79

Takara Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 350.47 356.70 362.69 368.18 373.79

Competitive Comparison of Takara Bio's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Takara Bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takara Bio's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Takara Bio's Cyclically Adjusted PS Ratio falls into.



Takara Bio Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Takara Bio's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=114.362/107.2000*107.2000
=114.362

Current CPI (Mar. 2024) = 107.2000.

Takara Bio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 39.688 98.000 43.414
201409 51.422 98.500 55.964
201412 52.501 97.900 57.488
201503 72.050 97.900 78.894
201506 47.843 98.400 52.122
201509 62.251 98.500 67.749
201512 61.861 98.100 67.599
201603 74.932 97.900 82.050
201606 52.369 98.100 57.227
201609 57.243 98.000 62.617
201612 61.836 98.400 67.366
201703 72.499 98.100 79.224
201706 52.776 98.500 57.437
201709 64.535 98.800 70.022
201712 70.755 99.400 76.307
201803 80.272 99.200 86.746
201806 73.471 99.200 79.396
201809 70.780 99.900 75.952
201812 70.738 99.700 76.059
201903 82.655 99.700 88.873
201906 71.835 99.800 77.161
201909 64.775 100.100 69.369
201912 67.333 100.500 71.822
202003 83.104 100.300 88.821
202006 57.617 99.900 61.827
202009 86.824 99.900 93.168
202012 100.950 99.300 108.981
202103 137.332 99.900 147.367
202106 126.828 99.500 136.643
202109 135.190 100.100 144.779
202112 117.161 100.100 125.471
202203 183.022 101.100 194.065
202206 117.112 101.800 123.324
202209 153.510 103.100 159.615
202212 229.363 104.100 236.193
202303 148.950 104.400 152.945
202306 76.203 105.200 77.652
202309 82.547 106.200 83.324
202312 88.178 106.800 88.508
202403 114.362 107.200 114.362

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Takara Bio  (TSE:4974) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Takara Bio's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1034.00/373.79
=2.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Takara Bio was 14.83. The lowest was 2.56. And the median was 9.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Takara Bio Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Takara Bio's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Takara Bio (TSE:4974) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (TSE:4974) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.

Takara Bio (TSE:4974) Headlines

No Headlines